TITLE

Chiron Boosts M&A Capabilities

AUTHOR(S)
Appin, Rick
PUB. DATE
August 1999
SOURCE
Mergers & Acquisitions Report;08/23/99, Vol. 12 Issue 34, p3
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Reports on the boosting of merger and acquisition (M&A) capabilities of Chiron Corp. by hiring Joyce Lonergan, an M&A specialist. Overview of Lonergan's record; Plan of divestiture.
ACCESSION #
2196217

 

Related Articles

  • Chiron Acquires PathoGenesis; Few Short-Term Synergies Seen. Boswell, Clay // Chemical Market Reporter;08/21/2000, Vol. 258 Issue 8, p1 

    Reports on the acquisition of PathoGenesis Corporation by Chiron Corporation. Cost of the acquisition; Terms of the agreement; Information on the tobramycin solution for inhalation product of PathoGenesis; Commercial products of Chiron; Revenues of Chiron between 1998 and 1999.

  • Chiron Moves Up.  // Pharmaceutical Executive;Jul2003, Vol. 23 Issue 7, p19 

    Reports on the acquisition of the vaccine manufacturer PowderJect Pharmaceuticals by Chiron Corp. in Great Britain.

  • Novartis Creates New Vaccines Division Following Close of Chiron Deal. Van Arnum, Patricia // Pharmaceutical Technology;Jun2006, Vol. 30 Issue 6, p20 

    The article reports on Novartis' acquisition of Chiron Corp. to create a vaccines and diagnostics division, named Novartis Vaccines and Diagnostics. The merger was approved by Chiron shareholders during a meeting. The division consists of two businesses, namely Novartis Vaccines and a...

  • Swooping for biotech. Wadman, Meredith // Nature;9/22/2005, Vol. 437 Issue 7058, p475 

    Reports on the plan of pharmaceutical company Novartis AG to acquire biotechnology firm Chiron Corp. to expand its drug pipeline in the U.S. Challenges of the biotechnology industry in delivering growth and value to investors; Significance of biomedical research to pharmaceutical firms; Growth...

  • PowderJect Close to Sale.  // Chemical Market Reporter;5/19/2003, Vol. 263 Issue 20, p2 

    Reports on the acquisition of PowderJect Pharmaceuticals PLC by Chiron Corp. in Great Britain.

  • Novartis Buyout of Chiron. Koroneos, George // Pharmaceutical Technology;Dec2005, Vol. 29 Issue 12, p28 

    The article presents information on the merger of two pharmaceutical companies namely Novartis AG and Chiron Corp. Switzerland-based Novartis has signed an agreement to acquire California-based Chiron for $5.1 billion. This agreement took place after being rejected initially, by the vaccine...

  • A Shot in the Arm. Kher, Unmesh // Time;1/9/2006, Vol. 167 Issue 2, pA4 

    The article reports on Novartis's planned acquisition of the troubled drug company Chiron. Chiron was partially responsible for the 2004 flu-vaccine shortage, begun when the company dumped 48 million doses of the vaccine due to contamination. Chiron's stock fell and the company was having...

  • UK biotech sector loses flagship PowderJect to Chiron. Mitchell, Pete // Nature Biotechnology;Jul2003, Vol. 21 Issue 7, p717 

    Reports that Great Britain's profitable biotechnology company PowderJect PLC is losing its independence to its U.S. rival company Chiron Corp. in a multi million cash deal. Impact of this merger on Great Britain's biotechnology industry; Expansion of the flu vaccine market ; Benefits enjoyed by...

  • Chiron's manufacturing misfortunes boost competitors. Sheridan, Cormac // Nature Biotechnology;Oct2005, Vol. 23 Issue 10, p1191 

    The article focuses on problems faced by Chiron Corp., the world's second largest flu vaccine supplier. Chiron's ongoing problems in influenza vaccine production have raised serious questions about the Emeryville, California company's future ability to compete in this particular segment of the...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics